Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer


23 Nov 2019


Poster display session


Tumour Site

Colon and Rectal Cancer


Ahmet Bilici


Annals of Oncology (2019) 30 (suppl_9): ix30-ix41. 10.1093/annonc/mdz421


A. Bilici1, B. Cakan1, T. Demir2, B.B. Oven3, O. Acikgoz1, J. Hamdard1, O.F. Olmez1, O. Olmuscelik1, M. Seker2, O. Yildiz1

Author affiliations

  • 1 Department Of Medical Oncology, Medipol University, Medical Faculty, 34214 - Istanbul/TR
  • 2 Department Of Medical Oncology, Bezmialem Vakif University, 34210 - Istanbul/TR
  • 3 Department Of Medical Oncology, Bahceşehir University, Medical Faculty, Istanbul/TR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 120P


The prognostic importance of platelet-to-lymphocyte ratio(PLR)has been also investigated in some cancer types including colorectal cancer (CRC).Several studies have found that PLR is associated with poor prognosis in patients with CRC,but,the results are controversial.The aim of this study was to investigate the predictive and prognostic value of PLR,and the relationship between PLR and tumor localization.


A total of 201 patients with metastatic CRC and candidate to systemic treatments were retrospectively analyzed.Pretreatment complete blood cell count was evaluated to calculate PLR.The cutoff value for PLR was defined by the receiver operating characteristic(ROC)curve analysis and threshold value of 205.5 as best cut-off value was found.The prognostic and predictive significance of PLR was evaluated by univariate and logistic regression analysis.


Significant relationship was detected between PLR and BRAF mutation,tumor localization.The higher rate of BRAF mutation was significantly detected for patients with PLRhigh(> 205.5)compared to those with PLRlow(<205.5)(p = 0.006).In addition,PLR was significantly higher in tumors located on the right colon than those with tumor on the left colon(p = 0.026).PLR, the presence of the primary tumor surgery, tumor localization, the presence of metastasectomy for progression-free survival(PFS)andPLR,age, BRAF mutation and the type of targeted therapy for overall survival(OS)were found to be prognostic factors by univariate analysis.Moreover,a logistic regression analysis indicated that PLR and the presence of metastasectomy were found to be an independent factors for predicting response to systemic treatment(p < 0.001,OR:0.30, 95%CI 0.16-0.34 and p = 0.020,OR: 0.40,95%CI 0.18-0.38,respectively).


Our results showed that pretreatment PLR was readily feasible and simple biomarker predicting response to treatment and survival,in addition it was significantly associated with tumor localization for patients with metastatic CRC.PLR may reflect immunogenic phenotype of patients with CRC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.